Sage Therapeutics, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$117.8M
Doctors Paid
8,180
Transactions
25,057
2024 Total
$20.9M
Payment Breakdown by Category
Research$112.2M (95.3%)
Consulting$2.6M (2.2%)
Food & Beverage$440,359 (0.4%)
Royalty/License$398,560 (0.3%)
Travel$210,072 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $112.2M | 8,261 | 95.3% |
| Consulting Fee | $2.6M | 814 | 2.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.7M | 122 | 1.4% |
| Food and Beverage | $440,359 | 15,209 | 0.4% |
| Royalty or License | $398,560 | 20 | 0.3% |
| Travel and Lodging | $210,072 | 572 | 0.2% |
| Space rental or facility fees (teaching hospital only) | $154,500 | 8 | 0.1% |
| Compensation for serving as faculty or as a speaker for a medical education program | $23,057 | 13 | 0.0% |
| Grant | $10,000 | 1 | 0.0% |
| Education | $2,119 | 36 | 0.0% |
| Gift | $252.92 | 1 | 0.0% |
Payments by Type
Research
$112.2M
8,261 transactions
General
$5.5M
16,796 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A PHASE 3, OPEN-LABEL, 1-YEAR STUDY OF THE SAFETY, TOLERABILITY, AND NEED FOR RE-TREATMENT WITH SAGE-217 IN ADULT SUBJECTS WITH MAJOR DEPRESSIVE DISORDER | $19.0M | 1 | 2,294 |
| A PHASE 3, MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY OF SAGE-217 IN THE TREATMENT OF ADULT SUBJECTS WITH MAJOR DEPRESSIVE DISORDER | $12.8M | 0 | 1,334 |
| A COMPARATIVE STUDY OF SAGE-217 PLUS SERTRALINE VERSUS PLACEBO PLUS SERTRALINE IN ADULTS WITH MAJOR DEPRESSIVE DISORDER | $10.3M | 0 | 846 |
| A Phase 3, Open-Label, 1-Year Study of the Safety, Tolerability, and Need for Re-Treatment with SAGE-217 in Adult Subjects with Major Depressive Disorder | $7.1M | 0 | 119 |
| A STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SAGE-217 IN PARTICIPANTS WITH SEVERE POSTPARTUM DEPRESSION (PPD) | $4.7M | 0 | 918 |
| Study to Evaluate SAGE-324 in Participants With Essential Tremors | $4.3M | 0 | 89 |
| A Study to Evaluate the Effect of SAGE-718 on Cognitive Function in Participants With Huntington's Disease (HD) | $3.8M | 0 | 51 |
| 217-MDD-303 | $3.7M | 1 | 259 |
| A PHASE 1, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, COMBINED SINGLE AND MULTIPLE ASCENDING DOSE STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF SAGE-904 ORAL SOLUTION IN HEALTHY SUBJECTS | $3.0M | 0 | 50 |
| A Study to Evaluate the Long-term Safety and Tolerability of SAGE-324 in Participants With Essential Tremor | $2.7M | 0 | 66 |
| A PHASE 1, OPEN-LABEL, 3-PART, 2-PERIOD, FIXED-SEQUENCE STUDY TO EVALUATE THE EFFECT OF RIFAMPIN, PRIMIDONE, AND ITRACONAZOLE ON THE PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF SAGE-324 IN HEALTHY PARTICIPANTS | $2.3M | 0 | 21 |
| A PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED, DOSE-RANGING STUDY EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF SAGE-324 MONOTHERAPY AND ADJUNCTIVE THERAPY WITH PROPRANOLOL IN THE TREATMENT OF INDIVIDUALS WITH ESSENTIAL TREMOR | $2.0M | 0 | 312 |
| A Study to Evaluate the Effects of SAGE-718 in Participants With Parkinson's Disease Cognitive Impairment | $1.7M | 0 | 28 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFECTS OF SAGE-718 IN PARTICIPANTS WITH MILD COGNITIVE IMPAIRMENT OR MILD DEMENTIA DUE TO ALZHEIMER'S DISEASE | $1.6M | 0 | 27 |
| NEUROCOGNITIVE EFFECTS, PHARMACOKINETICS, AND SAFETY OF SAGE-217 50 MG ADMINISTERED ALONE AND WITH ALPRAZOLAM OR ETHANOL IN HEALTHY PARTICIPANTS | $1.4M | 0 | 44 |
| A Study to Evaluate the Effects of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (AD) | $1.3M | 0 | 16 |
| A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effects of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease | $1.3M | 0 | 27 |
| 217-MDD-304 | $1.3M | 0 | 117 |
| A 28-Day Randomized, Placebo-Controlled, Double-Blind, Parallel Groups and Normative Comparison Study to Evaluate the Effect of SAGE-718 on Functioning Capacity in Participants With Huntington's Disease | $1.1M | 0 | 16 |
| AN OPEN-LABEL SINGLE-DOSE STUDY TO ASSESS THE ABSORPTION, DISTRIBUTION, METABOLISM, EXCRETION, AND MASS BALANCEOF SAGE-718 ORAL SOLUTION IN HEALTHY ADULT MEN | $1.1M | 0 | 9 |
| A PHASE 3, MULTICENTER, OPEN-LABEL SAFETY STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF SAGE-718 IN PARTICIPANTS WITH HUNTINGTON'S DISEASE | $1.0M | 0 | 18 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY, TOLERABILITY, AND EFFICACY OF SAGE-217 COMPARED TO PLACEBO IN ADULT SUBJECTS WITH COMORBID MAJOR DEPRESSIVE DISORDER AND INSOMNIA | $1.0M | 0 | 171 |
| A RANDOMIZED, DOUBLE-BLIND, ACTIVE-AND-PLACEBO CONTROLLED, 6-WAY CROSSOVER STUDY TO DETERMINE THE ABUSE POTENTIAL OF ORALLY ADMINISTERED SAGE-217 IN HEALTHY, NONDEPENDENT, RECREATIONAL CENTRAL NERVOUS SYSTEM DEPRESSANT USERS | $1.0M | 0 | 8 |
| A 28-DAY RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, PARALLEL GROUPS AND NORMATIVE COMPARISON STUDY TO EVALUATE THE EFFECT OF SAGE-718 ON FUNCTIONING CAPACITY IN PARTICIPANTS WITH HUNTINGTON'S DISEASE | $924,810 | 0 | 16 |
| A MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY, SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF BREXANOLONE IN THE TREATMENT OF ADOLESCENT FEMALE SUBJECTS WITH POSTPARTUM DEPRESSION | $890,069 | 2 | 80 |
| A STUDY TO EVALUATE THE EFFECT OF SAGE-718 ON COGNITIVE FUNCTION IN PARTICIPANTS WITH HUNTINGTON'S DISEASE (HD) | $882,141 | 0 | 50 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFECTS OF SAGE-718 IN PARKINSON'S DISEASE COGNITIVE IMPAIRMENT | $876,658 | 0 | 23 |
| A SINGLE-BLIND, 2-PERIOD, FIXED-SEQUENCE STUDY TO EVALUATE THE PHARMACOKINETICSOF PITAVASTATIN AND PITAVASTATIN LACTONE METABOLITE IN THE PRESENCE ANDABSENCE OF SAGE-324 AND THE SAFETY AND TOLERABILITY OF SAGE-324 IN HEALTHYPARTICIPANTS | $871,659 | 0 | 1 |
| A Phase 3, Multicenter, Open-label Safety Study to Evaluate the Long-term Safety and Tolerability of SAGE-718 in Participants With Huntington's Disease | $823,368 | 0 | 20 |
| 217-MDD-302 | $803,964 | 1 | 127 |
Payments by Medical Specialty
Top Paid Doctors — Page 2
| Doctor | Specialty | Location | Total | 2023 |
|---|---|---|---|---|
| Steven Arnold, Md, MD | Neurology | Philadelphia, PA | $17,420 | $0 |
| Dr. Dan Iosifescu, Md, MD | Psychiatry | Boston, MA | $17,038 | $0 |
| Dr. Susan Kornstein, M.d, M.D | Psychiatry | Richmond, VA | $16,844 | $0 |
| Rakesh Jain, Md, MD | Psychiatry | Lake Jackson, TX | $16,627 | $0 |
| Dr. Kristina Deligiannidis, Md, MD | Psychiatry | Glen Oaks, NY | $16,332 | $0 |
| Dr. Gerard Sanacora, M.d., Ph.d, M.D., PH.D | Psychiatry | New Haven, CT | $16,331 | $0 |
| Mr. Napoleon Higgins, M.d, M.D | Psychiatry | Friendswood, TX | $15,762 | $0 |
| Dr. Gustavo Alva, M.d, M.D | Psychiatry | Orange, CA | $14,977 | $0 |
| Dr. Brooke Kyle, M.d, M.D | Obstetrics & Gynecology | Springfield, OR | $14,881 | $0 |
| Unknown Provider | — | — | $14,597 | $0 |
| Linda Carpenter, Md, MD | Psychiatry | Providence, RI | $12,799 | $0 |
| Dr. Thomas Bleck, Md, MD | Critical Care Medicine | Chicago, IL | $12,575 | $0 |
| Dr. Carlyn Snyder, M.d, M.D | Psychiatry | New York, NY | $11,958 | $0 |
| Sagar Parikh, M.d, M.D | Psychiatry | Ann Arbor, MI | $11,958 | $0 |
| Dr. Michael Thase, Md, MD | Psychiatry | Philadelphia, PA | $11,837 | $0 |
| Jennifer Payne, M.d, M.D | Psychiatry | Charlottesville, VA | $11,781 | $0 |
| Dr. Gary Owens, M.d, M.D | Family Medicine | Glen Mills, PA | $11,554 | $0 |
| Dr. Andrew Nierenberg, Md, MD | Psychiatry | Boston, MA | $11,336 | $0 |
| Andrew Krystal, M.d, M.D | Psychiatry | Durham, NC | $10,275 | $0 |
| Dr. Judith Joseph, M.d, M.D | Psychiatry | Paterson, NJ | $10,058 | $0 |
| David Paydarfar, M.d, M.D | Neurology | Austin, TX | $10,000 | $0 |
| Charles Debattista, Md, MD | Psychiatry | Palo Alto, CA | $9,739 | $0 |
| Dr. Mark Wainwright, Md Phd, MD PHD | Neurology with Special Qualifications in Child Neurology | Seattle, WA | $9,675 | $0 |
| Gregory Mattingly, M.d, M.D | Psychiatry | Saint Charles, MO | $9,626 | $0 |
| Dr. Ranjit Bindra, M.d., Ph.d, M.D., PH.D | Radiation Oncology | New Haven, CT | $9,500 | $0 |
Ad
Top Products
- ZULRESSO $5.1M
- ZURZUVAE $4.9M
Associated Products (4)
- ZURZUVAE $5.4M
- ZULRESSO $5.1M
- Zulresso $429,711
- ZURANOLONE $10,475
Payment Categories
- Food & Beverage $440,359
- Consulting $2.6M
- Travel & Lodging $210,072
- Research $112.2M
- Royalties $398,560
About Sage Therapeutics, Inc.
Sage Therapeutics, Inc. has made $117.8M in payments to 8,180 healthcare providers, recorded across 25,057 transactions in the CMS Open Payments database. In 2024, the company paid $20.9M. The top product by payment volume is ZULRESSO ($5.1M).
Payments were distributed across 134 medical specialties. The top specialty by payment amount is Psychiatry ($3.2M to 606 doctors).
Payment categories include: Food & Beverage ($440,359), Consulting ($2.6M), Research ($112.2M), Travel & Lodging ($210,072), Royalties ($398,560).
Sage Therapeutics, Inc. is associated with 4 products in the CMS Open Payments database, including ZURZUVAE, ZULRESSO, and Zulresso.